Successful treatment with rituximab in a patient with an acquired factor V inhibitor.
Rituximab has already been successfully used to treat immune-mediated bleeding disorders such as acquired factor VIII inhibitor. We report here a case of severe acquired factor V (FV) inhibitor deficiency due to FV inhibitor which has been dramatically improved after rituximab.
Lebrun
Agnes
A
Department of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
Leroy-Matheron
Catherine
C
Arlet
Jean-Benoit
JB
Bartolucci
Pablo
P
Michel
Marc
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005165:Factor V / Q000187:drug effects / Q000378:metabolism; D005166:Factor V Deficiency / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D011517:Prothrombin Time; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D005165:Factor V